Overview

Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences
Immunomedics, Inc.

Treatments:

Docetaxel
Paclitaxel